Up­dat­ed: Sam­sung Bio leans in­to ADC, gene ther­a­py is an ‘area of in­ter­est’

South Ko­rea-head­quar­tered Sam­sung Bio is heav­i­ly ex­pand­ing its an­ti­body-drug con­ju­gate ca­pa­bil­i­ties and that gene ther­a­py is an “area of in­ter­est,” head of glob­al sales Kevin …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER